Quanterix Corp
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
QTRX$3.38+16.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Exhibit Description | FiledHerewith | Incorporated byReference herein from Form or Schedule | Filing Date | SEC File/Reg.Number |
|---|---|---|---|---|---|
| 2.1* | Amended and Restated Agreement and Plan of Merger, dated April 28, 2025, by and among the Registrant, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc. | 8-K | 04/29/2025 | 001-38319 | |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 10/02/2025 | 001-38319 | |
| 3.2 | Restated Bylaws. | 8-K | 10/02/2025 | 001-38319 | |
| 10.1+ | Akoya Biosciences, Inc. 2021 Equity Incentive Plan and form of stock option agreement thereunder | S-1/A | 04/12/2021 | 333-254760 | |
| 10.2+ | Akoya Biosciences, Inc. Form of Indemnification Agreement | 8-K | 12/13/2024 | 001-40344 | |
| 10.3* | Exclusivity (Equity) Agreement, dated November 17, 2015, by and between Akoya Biosciences, Inc. and The Board of Trustees of the Leland Stanford Junior University | S-1 | 03/26/2021 | 333-254760 | |
| 10.4* | Amendment No. 1 to the License Agreement, dated November 18, 2016, by and between Akoya Biosciences, Inc. and the Board of Trustees of the Leland Stanford junior University | S-1 | 03/26/2021 | 333-254760 | |
| 10.5* | License and Royalty Agreement, dated September 28, 2028, by and among Akoya Biosciences, Inc., PerkinElmer Health Services, Inc., Cambridge Research and Instrumentation, Inc., and VisEn Medical Inc. | S-1 | 03/26/2021 | 333-254760 | |
| 10.6* | Exclusive Patent License Agreement, dated June 26, 2018, by and between Akoya Biosciences, Inc. and the University of Washington | S-1 | 03/26/2021 | 333-254760 | |
| 10.7 | Cooperation Agreement, by and between Quanterix Corporation, Kent Lake PR LLC and Kent Lake Partners LP, dated August 4, 2025 | 8-K | 8/4/2025 | 001-38319 | |
| 31.1 | Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1 | Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | XBRL Taxonomy Extension Schema Document. | X | |||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | X | |||
| 101.DEF | XBRL Taxonomy Extension Definition. | X | |||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | X |
| * | Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished. |
|---|---|
| + | Management contract or compensatory plan or arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.